EARLY TOXICITY OF SCHEDULED HODGKIN LYMPHOMA IN CHILDREN

Abstract

Given the high number of patient survival rates with Hodgkin lymphoma (HL), most modern studies are focused on strategies to reduce the toxicity of treatment. The objectives of this study were to assess the early toxicity of the protocols DAL-HD (German working group for study and treatment of leukaemia in children) and SPbLH (St. Petersburg group on treatment of Hodgkin Lymphoma in children) compatible by effectiveness used in therapy of HL in children and adolescents. The study includes 143 HL patients aged between 3 and 18 (median-11.6 years), who received treatment from 1993 to 2015 under the following programs: DAL-HD-versions 87 and 90 and original research protocol SPBLH-05. Analysis of the direct toxicity of polychemotherapy (PCT) showed that the therapy according to DAL-HD protocol has a more pronounced emetogenicity and myelotoxicity than the SPbLH protocol. The most pronounced complications of PCT have been recorded in high-risk patients treated by DAL-HD program (hematotoxicity degree 3-4, dyspeptic syndrome with hypotrophy development). By reducing the combined doses of anthracycline antibiotics and alkylating agents, therapy by SPbLH protocol is accompanied by less pronounced side effects while maintaining a high level of common and relapsed survival. Thus, risk-adapted SPbLH programme can be recommended for the treatment of children and adolescents suffering from HL.

Keywords

• hodgkin lymphoma in children
• risk-adapted therapy
• dal-hd protocol
• spblh
• early toxicity
• cardiotoxicity